Abstract
In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin were assessed against 20 carbapenem-resistant clinical isolates with different mechanisms of carbapenem resistance. Bactericidal activity was achieved in 90% of all bacteria assayed using combinations of polymyxin B, doripenem, and rifampin against five each of the carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli isolates studied. Combinations with these antibacterials may provide a strategy for treatment of patients infected with such organisms.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acinetobacter Infections / drug therapy
-
Acinetobacter Infections / microbiology
-
Acinetobacter baumannii / drug effects*
-
Acinetobacter baumannii / isolation & purification
-
Anti-Bacterial Agents / administration & dosage*
-
Carbapenems / administration & dosage*
-
Doripenem
-
Drug Combinations
-
Drug Resistance, Multiple, Bacterial
-
Escherichia coli / drug effects*
-
Escherichia coli / isolation & purification
-
Escherichia coli Infections / drug therapy
-
Escherichia coli Infections / microbiology
-
Humans
-
In Vitro Techniques
-
Klebsiella Infections / drug therapy
-
Klebsiella Infections / microbiology
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / isolation & purification
-
Microbial Sensitivity Tests
-
Polymyxin B / administration & dosage*
-
Pseudomonas Infections / drug therapy
-
Pseudomonas Infections / microbiology
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / isolation & purification
-
Rifampin / administration & dosage*
-
beta-Lactam Resistance
Substances
-
Anti-Bacterial Agents
-
Carbapenems
-
Drug Combinations
-
Doripenem
-
Polymyxin B
-
Rifampin